Amelia Technologies LLC Profile last edited on: 5/22/2023
CAGE: 81HR5
UEI: H1EQZ5W49ZV3
Business Identifier: DNA damage accumulation as people age 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
1121 5th Street NW
Washington, DC 20001
Washington, DC 20001
| (202) 803-2614 |
| info@ameliatechnologies.com |
| www.ameliatechnologies.com |
Location: Single
Congr. District: 00
County: District of Columbia
Congr. District: 00
County: District of Columbia
Public Profile
With laboratories and offices located at Rockville, MD and a presence in Washington DC, Amelia Technologies LLC is a rapidly expanding biotechnology company positioning itself in the space between academia and industry and strucrured around collaborating with local startups and academic institutions in the D. area. Anchored in achieving a deeper understanding of what happens to human health when, as we gae, the individual's DNA accumulates damage. The effort is to apply and to development technologies designed to quantify DNA damage in cells and to provide insights into therapeutics for the aging disorders that occur because of this damage.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 1742206632 | 2 | NIH | $274,459 | |
| Project Title: EcoWell- A planet in a plate. | ||||
| 2023 | 2 | NIH | $1,929,804 | |
| Project Title: Barcoded human cells engineered with heterozygous genetic diversity to uncover toxicodynamic variability | ||||
| 2023 | 2 | NIH | $1,919,530 | |
| Project Title: Optimization of the UValidate Platform to Measure Genotoxicity Associated with Current Problematic UV Chemical Blockers | ||||
| 2020 | 1 | NIH | $274,324 | |
| Project Title: The development of FastMyco ¢ : a novel isothermal colorimetric assay for the rapid detection of mycoplasma contamination | ||||
Key People / Management
Mark C Chirikjian -- CEO
Lucia Dussan -- COO
Jia Fu -- Scientist
Jay George
Peter Sykora -- CSO
Lucia Dussan -- COO
Jia Fu -- Scientist
Jay George
Peter Sykora -- CSO
Company News
There are no news available.
